
William J Gibson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11931221/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings. Circulation, 2011, 123, 1400-1409.	1.6	688
2	BET Bromodomain Inhibition of <i>MYC</i> -Amplified Medulloblastoma. Clinical Cancer Research, 2014, 20, 912-925.	7.0	296
3	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	21.4	214
4	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics, 2016, 48, 848-855.	21.4	174
5	SWELL1 is a regulator of adipocyte size, insulin signalling and glucose homeostasis. Nature Cell Biology, 2017, 19, 504-517.	10.3	111
6	EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection. Cell, 2016, 164, 884-895.	28.9	108
7	ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genetics, 2015, 208, 345-350.	0.4	73
8	Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nature Communications, 2020, 11, 2517.	12.8	60
9	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget, 2015, 6, 1327-1339.	1.8	50
10	Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis. Journal of Thrombosis and Thrombolysis, 2020, 49, 1-9.	2.1	36
11	<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. Clinical Cancer Research, 2019, 25, 334-345.	7.0	17
12	Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Scientific Reports, 2016, 6, 25521.	3.3	13
13	Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute CoronaryÂSyndrome. Journal of the American College of Cardiology, 2018, 72, 129-136.	2.8	12
14	Response to Letter Regarding Article, "Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings― Circulation, 2011, 124	1.6	2